该贷款将为硼中子俘获治疗中心的建设提供更多助力，争取该中心在2025年年底开幕及开始营运，为有 需要癌症患者提供硼中子治疗服务。凭借博鰲乐城先行区的支持政策及以该中心作为示范，集团未来致 力发展建构覆盖中国的硼中子俘获治疗中心网络，发展特许经营医院，以创造更多的收入。 中国生物科技服务(08037)发布公告，于2025年9月9日，鹏博(海南)硼中子医疗科技有限公司(鹏博(海 南)，于中国成立的有限公司，并于本公告日期为公司的间接全资附属公司，作为借款人)与海南农村商 业银行股份有限公司琼海支行(作为贷款人)订立一份贷款合同。据此，贷款人同意向鹏博(海南)提供本 金最高为人民币1.8亿元的贷款。 ...

该贷款将为硼中子俘获治疗中心的建设提供更多助力，争取该中心在2025年年底开幕及开始营运，为有 需要癌症患者提供硼中子治疗服务。凭借博鰲乐城先行区的支持政策及以该中心作为示范，集团未来致 力发展建构覆盖中国的硼中子俘获治疗中心网络，发展特许经营医院，以创造更多的收入。 智通财经APP讯，中国生物科技服务(08037)发布公告，于2025年9月9日，鹏博(海南)硼中子医疗科技有 限公司(鹏博(海南)，于中国成立的有限公司，并于本公告日期为公司的间接全资附属公司，作为借款 人)与海南农村商业银行股份有限公司琼海支行(作为贷款人)订立一份贷款合同。据此，贷款人同意向鹏 博(海南)提供本金最高为人民币1.8亿元的贷款。 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 保證 ： (1) 抵押鵬博（海南）名下位於博鰲樂城先行區的土地使用權、 地上在建工程，以及硼中子治療的醫療設備； 反擔保 ： 鑑於第三方擔保人為該貸款提供保證擔保，本公司將向第三 方擔保人提供連帶責任保證，且鵬博（海南）的直接控股公司 將質押鵬博（海南）的100%股權予第三方擔保人，作為反擔保。 自願公告 銀行向本公司附屬公司授出貸款 本公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司，統稱 為「本集團」）作出之自願公告。 本公司之董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年九月九日，鵬博（海 南）硼中子醫療科技有限公司（「鵬博（海南）」）（於中華人民共和國（「中國」）成立 之有限公司，並於本公告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED （股份代號：8037） 補充公告 須予披露的交易 一名投資者投資本公司附屬公司 謹此提述中國生物科技服務控股有限公司日期為二零二五年七月十一日之公告， 內容有關華大松禾投資於鵬博（海南）（「該公告」）。除文義另有所指外，於本公告 內所採用之詞彙與該公告內所界定者具有相同涵義。 本公司謹此就該投資提供以下補充資料。 交易架構 根據中國相關法律法規，中國企業須就其企業境外投資(ODI)向相關中國政府機關 完成若干備案（包括向地方發展和改革委員會備案以及其後向地方外匯管理局登 記）。有關備案乃為監管及監察中國企業或個人所作出的境外直接投資。由於華 大松禾（為中國企業）正透過認購Dynamic Healthcare（其為一家在英屬處女群島註 冊成立之公司）的股份進行境外直接投資，因此，該投資須進行企業境外投資備案， 其一般需要一至三個 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | 本月底法定/ ...

Core Viewpoint - China Biotechnology Services (08037.HK) reported a significant improvement in financial performance for the six months ending June 30, 2025, with a revenue increase of 19.8% year-on-year, indicating effective cost control measures and compensation income from insurance claims [1] Financial Performance - Revenue reached HKD 38.872 million, up 19.8% compared to the previous year [1] - Gross profit was HKD 2.542 million, a recovery from a gross loss of HKD 3.107 million in the same period last year [1] - The loss attributable to owners of the company was HKD 32.006 million, a significant reduction of 60.0% from HKD 79.917 million in the prior year [1] - Basic loss per share was HKD 0.033 [1] Operational Improvements - The improvement in operational performance was primarily due to successful implementation of cost control measures, leading to an increase in gross margin and a reduction in administrative expenses [1] - The company received approximately HKD 13.7 million in compensation income related to damages from heavy rainfall affecting construction sites in Hainan during 2024 [1]

Core Insights - China Biotechnology Services (08037) reported a mid-year revenue of HKD 38.872 million for 2025, representing a year-on-year increase of 19.79% [1] - The company recorded a loss attributable to shareholders of HKD 32.006 million, which is a reduction of 59.95% compared to the previous year [1] - The loss per share is HKD 0.033 [1] Financial Performance - Revenue for the first half of 2025 reached HKD 38.872 million, showing a growth of 19.79% year-on-year [1] - The loss attributable to shareholders decreased significantly by 59.95%, amounting to HKD 32.006 million [1] - The earnings per share were reported at HKD 0.033 [1] Key Factors for Improvement - The improvement in loss is primarily attributed to successful cost control measures implemented by the company, which led to an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 13.7 million related to insurance claims for damages caused by heavy rainfall affecting construction sites in Hainan in 2024 [1]

[Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=2&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) The company reported a significant reduction in losses across all key metrics, driven by revenue growth and a shift from gross loss to gross profit Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income Summary | Metric | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 38,872 | 32,449 | +19.8% | | Gross Profit/(Loss) | 2,542 | (3,107) | Turned from loss to profit | | Operating Loss | (19,308) | (124,588) | Loss narrowed by 84.5% | | Loss Before Tax | (37,159) | (126,258) | Loss narrowed by 70.6% | | Loss for the Period | (36,753) | (125,731) | Loss narrowed by 70.8% | | Loss Attributable to Owners of the Company | (32,006) | (79,917) | Loss narrowed by 60.0% | | Basic and Diluted Loss Per Share (HKD) | (0.033) | (0.083) | Loss narrowed by 60.2% | [Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) The company's total assets increased slightly, while current assets decreased and total liabilities rose, leading to a decline in total equity Condensed Consolidated Statement of Financial Position Summary | Metric | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 538,426 | 529,955 | +1.6% | | Total Non-Current Assets | 502,598 | 466,860 | +7.6% | | Total Current Assets | 35,828 | 63,095 | -43.2% | | Total Equity | 211,886 | 242,388 | -12.6% | | Total Liabilities | 326,540 | 287,567 | +13.5% | | Total Non-Current Liabilities | 130,849 | 94,953 | +37.8% | | Total Current Liabilities | 195,691 | 192,614 | +1.6% | - Property, plant and equipment increased to **HKD 248,508 thousand** (December 31, 2024: **HKD 219,341 thousand**), primarily due to additions to construction in progress[5](index=5&type=chunk) - Bank and cash balances decreased to **HKD 11,290 thousand** (December 31, 2024: **HKD 18,913 thousand**), reflecting the use of funds for operations and the construction of the BNCT center[5](index=5&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of the Group's business, accounting policies, and financial performance, highlighting going concern uncertainties and mitigation efforts [1. General Information](index=6&type=section&id=1.%20General%20Information) The company is a GEM-listed entity with diverse healthcare businesses in Hong Kong and mainland China, including medical testing, immunotherapy, and BNCT services - The company's main businesses include medical laboratory testing, health checks, and insurance brokerage services in Hong Kong, as well as oncology immune cell therapy, health management, BNCT services, and sales of healthcare pharmaceutical products in mainland China[7](index=7&type=chunk) - The company is listed on GEM of The Stock Exchange of Hong Kong Limited[8](index=8&type=chunk) [2. Basis of Preparation and Accounting Policies](index=6&type=section&id=2.%20Basis%20of%20Preparation%20and%20Accounting%20Policies) The interim financial information is prepared under HKAS 34, with significant going concern uncertainties due to losses and current liabilities exceeding current assets, addressed by cost control and financing efforts - For the six months ended **June 30, 2025**, the Group recorded a loss of approximately **36,753 thousand HKD**, with current liabilities exceeding current assets by approximately **159,863 thousand HKD**, indicating significant uncertainty about its ability to continue as a going concern[11](index=11&type=chunk) - To alleviate liquidity pressure, the Group is implementing operational plans to control costs, optimize resource allocation, reduce staff costs, and actively seeking alternative financing, borrowings, and fundraising solutions (such as placing shares and issuing convertible bonds)[13](index=13&type=chunk) - The Group is exploring the realization of financial assets measured at fair value through other comprehensive income to support operations and growth[13](index=13&type=chunk) [3. Revenue](index=8&type=section&id=3.%20Revenue) The Group's revenue increased by **19.8%**, primarily driven by a substantial rise in insurance brokerage services, partially offset by a decline in medical laboratory testing and health check services Segment Revenue by Service Category | Service Category | 2025 (HKD thousands) | 2024 (HKD thousands) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Medical Laboratory Testing and Health Check Services | 16,164 | 19,729 | -18.1% | | Insurance Brokerage Services | 22,640 | 12,255 | +84.7% | | Sales and Distribution of Healthcare-related and Pharmaceutical Products and Other Services | – | 437 | -100% | | Logistics Services | 68 | 28 | +142.9% | | **Total Revenue** | **38,872** | **32,449** | **+19.8%** | [4. Segment Information](index=8&type=section&id=4.%20Segment%20Information) The Group operates six segments, with significant growth in insurance brokerage and BNCT profitability, with capital expenditure focused on BNCT and medical/healthcare and immunotherapy segments remain in loss Segment Revenue and (Loss)/Profit **Segment Revenue (For the six months ended June 30):** | Segment | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Medical Laboratory Testing and Healthcare-related Services | 16,164 | 19,729 | | Insurance Brokerage | 22,640 | 12,255 | | Pharmaceutical Products | – | 437 | | Other | 68 | 28 | | **Total** | **38,872** | **32,449** | **Segment (Loss)/Profit (For the six months ended June 30):** | Segment | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Medical Laboratory Testing and Healthcare-related Services | (14,788) | (71,707) | | Immunotherapy | (13,118) | (25,206) | | Boron Neutron Capture Therapy | 8,776 | (3,147) | | Insurance Brokerage | 1,870 | (62) | | Pharmaceutical Products | (720) | (485) | | Other | (340) | (342) | | **Total** | **(18,320)** | **(100,949)** | - Total capital expenditure in **2025** amounted to **22,700 thousand HKD**, with **22,692 thousand HKD** allocated to Boron Neutron Capture Therapy[21](index=21&type=chunk) - Impairment loss on right-of-use assets in **2025** was **3,524 thousand HKD**[21](index=21&type=chunk) [5. Other Income and Gains/(Losses), Net](index=12&type=section&id=5.%20Other%20Income%20and%20Gains%2F%28Losses%29%2C%20Net) Net other income and gains for the period significantly turned from a loss in **2024** to a gain, primarily due to storm damage compensation and exchange gains Other Income and Gains/(Losses), Net | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Compensation Income | 13,695 | – | | Exchange Gains/(Losses), Net | 6,576 | (12,504) | | Loss on Derecognition of Property, Plant and Equipment | – | (15,901) | | **Total** | **21,728** | **(26,460)** | - Compensation income of **13,695 thousand HKD** relates to insurance claims for storm damage at a Hainan construction site in **2024**[23](index=23&type=chunk) [6. Finance Costs](index=12&type=section&id=6.%20Finance%20Costs) Finance costs substantially increased due to higher interest on convertible bonds, put option liabilities, and other borrowings Finance Costs Breakdown | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest on Bank Borrowings | 523 | 814 | | Interest on Other Borrowings | 4,191 | 1,115 | | Interest on Loans from Controlling Shareholder | 1,291 | 205 | | Interest on Convertible Bonds and Put Option Liabilities | 6,294 | 2,158 | | Interest on Lease Liabilities | 237 | 394 | | **Total** | **12,536** | **4,686** | [7. Loss Before Tax](index=13&type=section&id=7.%20Loss%20Before%20Tax) Loss before tax significantly narrowed, driven by reduced research and development, staff costs, and inventory write-downs, partially offset by impairment loss on right-of-use assets Loss Before Tax Components | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Research and Development Costs | 5,965 | 17,593 | | Staff Costs (Salaries, Bonuses and Allowances) | 25,021 | 38,985 | | Write-down of Inventories | 194 | 5,089 | | Derecognition of Property, Plant and Equipment | – | 15,901 | | Impairment Loss on Right-of-Use Assets | 3,524 | – | [8. Income Tax Credit](index=13&type=section&id=8.%20Income%20Tax%20Credit) Income tax credit for the period was slightly lower than the prior year, primarily derived from deferred income tax Income Tax Credit Breakdown | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Current Income Tax | (195) | (78) | | Deferred Income Tax | 601 | 605 | | **Total** | **406** | **527** | [9. Dividends](index=14&type=section&id=9.%20Dividends) The Board does not recommend any dividend payment for the current interim period, consistent with the prior year - The Board does not recommend the payment of any dividend for the period[27](index=27&type=chunk) [10. Loss Per Share](index=14&type=section&id=10.%20Loss%20Per%20Share) Basic and diluted loss per share attributable to owners of the Company significantly improved, reflecting a reduction in per-share losses Basic and Diluted Loss Per Share | Metric | 2025 (HKD) | 2024 (HKD) | | :--- | :--- | :--- | | Basic and Diluted Loss Per Share | (0.033) | (0.083) | - The weighted average number of ordinary shares used for calculating basic and diluted loss per share increased from **963,231 thousand** in **2024** to **975,731 thousand** in **2025**[29](index=29&type=chunk) [11. Property, Plant and Equipment](index=14&type=section&id=11.%20Property%2C%20Plant%20and%20Equipment) The primary addition to property, plant and equipment for the period was significant investment in construction in progress - Main addition was **22,692 thousand HKD** for construction in progress[30](index=30&type=chunk) [12. Goodwill](index=15&type=section&id=12.%20Goodwill) The carrying amount of goodwill increased, primarily influenced by exchange differences during the period Goodwill Carrying Amount | Metric | June 30, 2025 (HKD thousands) | June 30, 2024 (HKD thousands) | | :--- | :--- | :--- | | Carrying Amount | 107,225 | 104,792 | | Exchange Differences | 3,331 | (2,389) | [13. Intangible Assets](index=15&type=section&id=13.%20Intangible%20Assets) The net carrying amount of intangible assets decreased, mainly due to amortisation expense, partially offset by exchange differences Intangible Assets Net Carrying Amount | Metric | June 30, 2025 (HKD thousands) | June 30, 2024 (HKD thousands) | | :--- | :--- | :--- | | Net Carrying Amount at End of Period | 32,013 | 52,623 | | Amortisation Expense | (4,005) | (4,036) | | Exchange Differences | 1,074 | (985) | [14. Trade and Other Receivables, Deposits and Prepayments](index=16&type=section&id=14.%20Trade%20and%20Other%20Receivables%2C%20Deposits%20and%20Prepayments) Net trade receivables increased, with a significant portion of deposits allocated to purchasing BNCT drugs from a Japanese pharmaceutical company Trade and Other Receivables, Deposits and Prepayments | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Net Trade Receivables | 7,988 | 7,033 | | Rental and Other Deposits | 56,799 | 51,822 | | Other Receivables | 8,246 | 14,012 | | Prepayments | 3,490 | 1,991 | | **Total** | **76,547** | **74,872** | - Rental and other deposits include **54,559 thousand HKD** (equivalent to **1,000,000,000 JPY**) as a deposit paid to a Japanese pharmaceutical company for Boron Neutron Capture Therapy drugs to be used at the Hainan BNCT Cancer Treatment Centre[32](index=32&type=chunk) [15. Trade Payables](index=17&type=section&id=15.%20Trade%20Payables) Total trade payables increased as of **June 30, 2025**, compared to **December 31, 2024** Trade Payables Ageing Analysis | Ageing | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | 0 to 90 days | 4,440 | 4,883 | | 91 to 180 days | 1,278 | 1,549 | | 181 to 365 days | 1,610 | 166 | | Over 365 days | 770 | 755 | | **Total** | **8,098** | **7,353** | [16. Convertible Bonds and Derivative Financial Liabilities](index=17&type=section&id=16.%20Convertible%20Bonds%20and%20Derivative%20Financial%20Liabilities) The Group's convertible bonds and related derivative financial liabilities, including written put option liabilities, saw increases in their fair values - In **December 2024**, convertible bonds with a principal amount of **6,000,000 USD** (approximately **47,100 thousand HKD**) were issued at an annual interest rate of **8.25%** and an initial conversion price of **1.20 HKD** per share[35](index=35&type=chunk) Convertible Bonds and Derivative Financial Liabilities | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Convertible Bonds - Liability Component | 42,919 | 41,635 | | Convertible Bonds - Fair Value of Derivative Component | 11,317 | 6,002 | | Written Put Option Liabilities | 45,065 | 40,480 | - The effective interest rate applied to the convertible bonds' liability component was **15.0%** (**2024**: **8.62%**)[36](index=36&type=chunk) [17. Borrowings](index=19&type=section&id=17.%20Borrowings) Total borrowings increased, primarily for working capital and BNCT center development, secured by various assets, with the Group complying with all financial covenants Total Borrowings and Analysis **Total Borrowings (HKD thousands):** | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Bank Borrowings | 33,981 | 25,981 | | Other Borrowings | 99,041 | 87,940 | | Loans from Controlling Shareholder | 28,074 | 24,772 | | **Total** | **161,096** | **138,693** | **Borrowings Analysis (HKD thousands):** | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Current Portion | 139,179 | 138,693 | | Non-Current Portion | 21,917 | – | - Borrowing interest rates range from **LPR minus 0.45% or 3.45%–3.85%** for bank borrowings, **6%–18%** for other borrowings, and **10%** for controlling shareholder loans[39](index=39&type=chunk) - Borrowings are primarily secured by construction in progress (**233,866 thousand HKD**), China land use rights (**11,799 thousand HKD**), property, plant and equipment (**10,743 thousand HKD**), other receivables (**1,864 thousand HKD**), intangible assets (**30,689 thousand HKD**), and a **47%** equity interest in a subsidiary[40](index=40&type=chunk)[41](index=41&type=chunk) - The Group has complied with the financial covenants of its borrowing facilities[42](index=42&type=chunk) [18. Contingent Liabilities](index=20&type=section&id=18.%20Contingent%20Liabilities) The Group reported no material contingent liabilities as of **June 30, 2025** - The Group had no material contingent liabilities[43](index=43&type=chunk) [19. Related Party Transactions](index=20&type=section&id=19.%20Related%20Party%20Transactions) Related party transactions for the period primarily included interest expenses paid to the controlling shareholder and key management personnel remuneration Related Party Transactions Summary | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest Expenses Paid to Controlling Shareholder | 1,291 | 205 | | Key Management Personnel Remuneration | 2,589 | 3,615 | [20. Events After Reporting Period](index=21&type=section&id=20.%20Events%20After%20Reporting%20Period) Post-reporting period events include a strategic financing agreement where BGI-Songhe will provide a loan to Pengbo (Hainan), convertible into Dynamic Healthcare shares - BGI-Songhe will provide a **30 million RMB** loan to Pengbo (Hainan), which will be converted into shares of Dynamic Healthcare Holdings Limited[46](index=46&type=chunk) - BGI-Songhe will hold up to **6.25%** of Dynamic Healthcare's enlarged issued share capital[46](index=46&type=chunk) [Financial Review](index=22&type=section&id=Financial%20Review) The financial review highlights a significant reduction in net loss, improved gross margin, and reduced operating expenses, despite increased finance costs - Revenue for the period was approximately **38.9 million HKD**, an increase of **19.8%** year-on-year, primarily driven by growth in the insurance brokerage services segment, partially offset by a decline in the medical laboratory testing and health check services segment[48](index=48&type=chunk) - Gross profit turned from a loss of approximately **3.1 million HKD** in the prior year to a profit of approximately **2.5 million HKD**, with gross margin improving to **6.5%**, mainly due to a significant reduction in inventory write-downs[49](index=49&type=chunk) - Selling and distribution expenses decreased by **44.6%** to **3.6 million HKD**, administrative expenses decreased by **52.0%** to **34.0 million HKD**, and research and development costs decreased by **66.1%** to **6.0 million HKD**, primarily due to reduced staff costs, fewer one-off legal claims, and lower late-stage clinical trial expenses[50](index=50&type=chunk)[51](index=51&type=chunk)[52](index=52&type=chunk) - Finance costs increased to **12.5 million HKD**, mainly due to additional bank and other borrowings for working capital and the construction of the BNCT Cancer Treatment Centre[53](index=53&type=chunk) - Net loss attributable to owners of the Company decreased by **60.0%** to **32.0 million HKD**, primarily due to cost control measures, improved gross margin, reduced administrative expenses, and **13.7 million HKD** in insurance compensation income[54](index=54&type=chunk) [Business Review](index=24&type=section&id=Business%20Review) The business review covers strategic financing, progress on the BNCT center, expanded drug cooperation, new insurance products, and advancements in CAR-T clinical trials - Pengbo (Hainan) secured **30 million RMB** in strategic financing from BGI-Songhe to strengthen its development foundation[55](index=55&type=chunk) - The BNCT Cancer Treatment Centre is under construction in Hainan, targeting opening and operation by **end of 2025**, having obtained medical institution practice license and medical device import approval[57](index=57&type=chunk) - Signed an MOU with STELLA PHARMA CORPORATION to expand cooperation for BNCT drug STEBORONINE® in China, including exclusive manufacturing and sales rights, with plans for localized production[58](index=58&type=chunk) - Collaborated with AXA Insurance (Bermuda) Limited to develop comprehensive medical insurance products covering BNCT cancer treatment costs and related services[59](index=59&type=chunk) - Shanghai Longyao's LY007 cell injection (China's first clinically approved CD20-targeted CAR-T therapy) has completed Phase I clinical trials, with Phase II trials planned to commence by **end of 2025**[61](index=61&type=chunk) - Phase I clinical results for LY007 cell injection have been presented at international conferences like ASCO and ASH, and invited for presentation at ICML and EHA[64](index=64&type=chunk) [Outlook](index=27&type=section&id=Outlook) The Group's outlook focuses on laboratory upgrades, expanding healthcare services, commercializing CAR-T products, operationalizing the BNCT center, and developing integrated treatment models and insurance products - The Group has upgraded its laboratory with Hong Kong's first customized virtual biochemistry immunoassay automation system, collaborating with institutions for contract research services and public health screening/vaccination programs[66](index=66&type=chunk) - Demand for health checks and related medical services is expected to continue growing due to increased public health awareness, an aging population, and rising demand for private healthcare services[67](index=67&type=chunk) - The Group aims to advance the commercialization of its CAR-T product LY007 cell injection, pushing for domestic Phase II clinical trials and commercial partnerships, including international patenting, with Phase II trials expected to start by **end of 2025**[68](index=68&type=chunk) - The Group is committed to ensuring the BNCT Cancer Treatment Centre is operational by **end of 2025**, planning a China-wide treatment network, developing franchised hospitals, and generating new revenue from equipment sales and related services[69](index=69&type=chunk) - Deepen industry-academic research integration with leading hospitals to explore a new "diagnosis-treatment integrated" BNCT model[70](index=70&type=chunk) - Strengthen cooperation with insurance companies to develop inclusive BNCT medical insurance products and establish patient referral partnerships with domestic hospitals to enhance accessibility and reduce financial burden[71](index=71&type=chunk) [Events After Reporting Period](index=29&type=section&id=Events%20After%20Reporting%20Period) Details of events after the reporting period are set out in Note 20 to the unaudited condensed consolidated financial statements - Details of events after the reporting period are set out in Note 20 to the unaudited condensed consolidated financial statements[73](index=73&type=chunk) [Liquidity, Financial Resources and Capital Structure](index=30&type=section&id=Liquidity%2C%20Financial%20Resources%20and%20Capital%20Structure) The Group's liquidity shows decreased cash balances and increased borrowings, with capital commitments for property, plant and equipment, and secured loans - Cash and bank balances decreased to **11,290 thousand HKD** (December 31, 2024: **18,913 thousand HKD**), primarily used for operating activities and the construction of the BNCT Cancer Treatment Centre[75](index=75&type=chunk) - Outstanding convertible bonds amounted to approximately **42,919 thousand HKD**, with an annual interest rate of **8.25%**, maturing on **December 27, 2026**[75](index=75&type=chunk) - Total borrowings increased to **161,096 thousand HKD** (December 31, 2024: **138,693 thousand HKD**), mainly due to additional borrowings for working capital and the development of the BNCT Cancer Treatment Centre[76](index=76&type=chunk) Financial Ratios | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Debt-to-Equity Ratio | 60.6% | 54.3% | | Current Ratio | **0.18 times** | **0.33 times** | - Capital commitments for property, plant and equipment increased to **153,210 thousand HKD** (December 31, 2024: **122,560 thousand HKD**)[79](index=79&type=chunk) - Borrowings are secured by Pengbo (Hainan)'s land use rights, construction in progress, property, plant and equipment, other receivables, intangible assets, and equity interest in a subsidiary[80](index=80&type=chunk)[81](index=81&type=chunk) - The Group has no material contingent liabilities and uses hedging instruments to manage foreign exchange and interest rate risks[82](index=82&type=chunk)[83](index=83&type=chunk) [Material Investments Held and Performance](index=33&type=section&id=Material%20Investments%20Held%20and%20Performance) The Group holds significant investments in precision cancer diagnostics companies, with strategic collaborations expected to generate synergies with its medical testing services - The Group holds investments in Pillar Biosciences, Inc and Zhengu Diagnostics Holdings Limited (precision cancer diagnostics companies) with a fair value of approximately **43,703 thousand HKD**, representing **8.12%** of total assets[84](index=84&type=chunk) - Pillar Biosciences, Inc recorded an unaudited loss of approximately **17,000,000 USD** in **2024**, and the Group received no dividend income from Pillar during the period[85](index=85&type=chunk) - Strategic cooperation with Pillar led to the establishment of Asia Molecular Diagnostics Laboratory Limited in Hong Kong, offering next-generation sequencing precision cancer diagnostic services, expected to generate synergies with the Group's medical testing services[85](index=85&type=chunk) [Material Acquisitions and Disposals of Subsidiaries and Associates](index=34&type=section&id=Material%20Acquisitions%20and%20Disposals%20of%20Subsidiaries%20and%20Associates) The Group did not engage in any material acquisitions or disposals of subsidiaries and associates during the reporting period - The Group did not undertake any material acquisitions or disposals of subsidiaries and associates during the period[86](index=86&type=chunk) [Employees and Remuneration Policy](index=34&type=section&id=Employees%20and%20Remuneration%20Policy) The Group's employee count slightly decreased, with remuneration policies based on performance, experience, and market rates, including various benefits and incentive schemes - As of **June 30, 2025**, the Group employed **133** full-time employees (**June 30, 2024**: **142**)[87](index=87&type=chunk) - Remuneration is determined based on performance, experience, and market rates, including discretionary bonuses, MPF scheme, retirement benefit scheme contributions, insurance and medical, training, and participation in share option and share award schemes[87](index=87&type=chunk) [Share Option Scheme](index=34&type=section&id=Share%20Option%20Scheme) The company adopted a share option scheme in **2024**, but no options were granted during the current reporting period - The company adopted a share option scheme on **June 6, 2024**, but no share options were granted during the period[88](index=88&type=chunk) [Share Award Scheme](index=34&type=section&id=Share%20Award%20Scheme) The company adopted a share award scheme in **2021**, but no shares were subscribed for, received, purchased, or granted under the scheme during the current period - The company adopted a share award scheme on **August 18, 2021**, but the trustee neither subscribed for, received, nor purchased any company shares, nor did the company grant any shares under the scheme during the period[89](index=89&type=chunk) [Directors' Rights to Acquire Shares or Debentures](index=35&

董事會會議通告 中國生物科技服務控股有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈將於二零二五年八月二十七日（星期三）舉行董事會會議，以（其中 包括）考慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之 未經審核簡明綜合中期業績，並考慮派付股息（如有）。 承董事會命 中國生物科技服務控股有限公司 主席兼執行董事 劉小林 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 香港，二零二五年八月十五日 於本公告日期，董事會包括四名執行董事，即劉小林先生（主席）、何詢先生、黃嵩先 生及尹燁博士；及三名獨立非執行董事，即鄢國祥先生、郭圓濤博士及張曉博士。 本公告的資料乃遵照 GEM 上市規則而刊載，旨在提供有關本公司的資料；董事願就本 公告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所 知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並 無遺漏任何事項，足以令致本公告或其所載任何陳述產生誤 ...

Core Viewpoint - China Biotechnology Services (08037) expects a significant reduction in losses for the first half of 2025, projecting a loss attributable to shareholders of no more than HKD 33 million, which is approximately 59% lower than the loss of HKD 79.917 million in the same period of 2024 [1] Group 1 - The improvement in operational performance is primarily attributed to successful cost control measures implemented by the company [1] - The company has experienced an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 14 million from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]